Skip to main content
Key Specialties
Anesthesiology Cardiology Dermatology Diabetology Endocrinology Gastroenterology and Hepatology General Medicine Geriatrics Hematology Infectious Diseases Internal Medicine Nephrology Neurology Obstetrics and Gynecology Oncology Ophthalmology Pediatrics Psychiatry Radiology Respiratory Medicine Rheumatology Surgery Urology
Congress Coverage
ASH 2024 Annual Meeting 2024 ESMO Congress 2024 ERS Congress 2024 EASD Congress 2024 ESC Congress 2024 EAN Congress 2024 ASCO Annual Meeting 2024 ACC Congress
Clinical Collections
Women’s Health Knowledge Hub Advances in Alzheimer’s

Navigating neuroimaging in Alzheimer disease care

PET imaging is playing an increasingly critical role in managing AD, but how can you effectively integrate it into clinical practice? Our expert-led program will empower you with practical strategies and real-world case studies.

This content is intended for healthcare professionals outside of the UK.
ADVANCED SEARCH
Log in
Top
Diabetology & Metabolic Syndrome
Published in:

Open Access 01-12-2024 | Late Onset Autoimmune Diabetes in Adults | Review

Prognosis and outcome of latent autoimmune diabetes in adults: T1DM or T2DM?

Authors: Zhipeng Zhou, Mingyue Xu, Pingjie Xiong, Jing Yuan, Deqing Zheng, Shenghua Piao

Published in: Diabetology & Metabolic Syndrome | Issue 1/2024

Login to get access

Abstract

Latent Autoimmune Diabetes in Adults (LADA) is a type of diabetes mellitus often overlooked in clinical practice for its dual resemblance to Type 1 Diabetes Mellitus (T1DM) in pathogenesis and to Type 2 Diabetes Mellitus (T2DM) in clinical presentation. To better understand LADA’s distinctiveness from T1DM and T2DM, we conducted a comprehensive review encompassing etiology, pathology, clinical features, treatment modalities, and prognostic outcomes. With this comparative lens, we propose that LADA defies simple classification as either T1DM or T2DM. The specific treatments for the disease are limited and should be based on the therapies of T1DM or T2DM that address specific clinical issues at different stages of the disease. It is crucial to identify LADA cases potentially misdiagnosed as T2DM, warranting prompt screening for poor blood sugar control, short-term blood sugar deterioration, and other conditions. If the prognosis for LADA is similar to T2DM, it can be managed as T2DM. However, if the prognosis fundamentally differs, early LADA screening is crucial to optimize patient outcomes and enhance research on tailored treatments. The pathogenesis of LADA is clear, so the prognosis may be the key to determining whether it can be classified as T2DM, which is also the direction of future research. On the one hand, this paper aims to provide suggestions for the clinical screening and treatment of LADA based on the latest progress and provide worthy directions for future research on LADA.
Literature
1.
Buzzetti R, Maddaloni E, Gaglia J, Leslie RD, Wong FS, Boehm BO. Adult-onset autoimmune diabetes. Nat Reviews Disease Primers. 2022;8:63.PubMedCrossRef
2.
Kumar A, de Leiva A. Latent autoimmune diabetes in adults (LADA) in Asian and European populations. Diab/Metab Res Rev. 2017;33.
3.
WHO. Classification of diabetes Mellitus. WHO; 2019.
4.
Buzzetti R, Tuomi T, Mauricio D, Pietropaolo M, Zhou Z, Pozzilli P, et al. Management of latent autoimmune diabetes in adults: a Consensus Statement from an International Expert Panel. Diabetes. 2020;69:2037–47.PubMedPubMedCentralCrossRef
5.
Chinese Endocrinologist Association CMDA. Consensus of Chinese experts on the diagnosis and treatment of latent autoimmune diabetes in adults(2021 Edition). Natl Med J China. 2021;101.
6.
Classification and Diagnosis of Diabetes. Standards of Medical Care in Diabetes-2022. Diabetes Care. 2022;45:S17–38.CrossRef
7.
Vauhkonen I, Niskanen L, Knip M, Ilonen J, Vanninen E, Kainulainen S, et al. Impaired insulin secretion in non-diabetic offspring of probands with latent autoimmune diabetes mellitus in adults. Diabetologia. 2000;43:69–78.PubMedCrossRef
8.
Cousminer DL, Ahlqvist E, Mishra R, Andersen MK, Chesi A, Hawa MI, et al. First Genome-Wide Association Study of Latent Autoimmune Diabetes in adults reveals novel insights linking Immune and metabolic diabetes. Diabetes Care. 2018;41:2396–403.PubMedPubMedCentralCrossRef
9.
Kawasaki E. Anti-islet autoantibodies in Type 1 diabetes. Int J Mol Sci. 2023;24.
10.
Deng C, Xiang Y, Tan T, Ren Z, Cao C, Huang G, et al. Altered peripheral B-Lymphocyte subsets in type 1 diabetes and latent autoimmune diabetes in adults. Diabetes Care. 2016;39:434–40.PubMedCrossRef
11.
Tan T, Xiang Y, Deng C, Cao C, Ren Z, Huang G, et al. Variable frequencies of peripheral T-lymphocyte subsets in the diabetes spectrum from type 1 diabetes through latent autoimmune diabetes in adults (LADA) to type 2 diabetes. Front Immunol. 2022;13:974864.PubMedPubMedCentralCrossRef
12.
Schloot NC, Pham MN, Hawa MI, Pozzilli P, Scherbaum WA, Schott M, et al. Inverse relationship between organ-specific autoantibodies and systemic Immune mediators in Type 1 diabetes and type 2 diabetes: action LADA 11. Diabetes Care. 2016;39:1932–9.PubMedCrossRef
13.
Piccioni A, Rosa F, Mannucci S, Manca F, Merra G, Chiloiro S et al. Gut microbiota, LADA, and type 1 diabetes Mellitus: an evolving relationship. Biomedicines. 2023;11.
14.
Löfvenborg JE, Ahlqvist E, Alfredsson L, Andersson T, Dorkhan M, Groop L, et al. Genotypes of HLA, TCF7L2, and FTO as potential modifiers of the association between sweetened beverage consumption and risk of LADA and type 2 diabetes. Eur J Nutr. 2020;59:127–35.PubMedCrossRef
15.
Katahira M, Tsunekawa T, Mizoguchi A, Yamaguchi M, Tsuru K, Takashima H, et al. Critical amino acid variants in HLA-DRB1 and -DQB1 allotypes in the development of classical type 1 diabetes and latent autoimmune diabetes in adults in the Japanese Population. Curr Issues Mol Biol. 2021;43:107–15.PubMedPubMedCentralCrossRef
16.
Chen W, Chen X, Zhang M, Huang Z. The association of human leukocyte antigen class II (HLA II) haplotypes with the risk of latent autoimmune diabetes of adults (LADA): evidence based on available data. Gene. 2021;767:145177.PubMedCrossRef
17.
Hernández M, Nóvoa-Medina Y, Faner R, Palou E, Esquerda A, Castelblanco E, et al. Genetics: is LADA just late onset type 1 diabetes? Front Endocrinol. 2022;13:916698.CrossRef
18.
Petrone A, Bugawan TL, Mesturino CA, Nisticò L, Galgani A, Giorgi G, et al. The distribution of HLA class II susceptible/protective haplotypes could partially explain the low incidence of type 1 diabetes in continental Italy (Lazio region). Tissue Antigens. 2001;58:385–94.PubMedCrossRef
19.
Pang H, Luo S, Huang G, Li X, Xie Z, Zhou Z. The Association of CTLA-4 rs231775 and rs3087243 polymorphisms with latent autoimmune diabetes in adults: a Meta-analysis. Biochem Genet. 2022;60:1222–35.PubMedCrossRef
20.
Lukacs K, Hosszufalusi N, Dinya E, Bakacs M, Madacsy L, Panczel P. The type 2 diabetes-associated variant in TCF7L2 is associated with latent autoimmune diabetes in adult europeans and the gene effect is modified by obesity: a meta-analysis and an individual study. Diabetologia. 2012;55:689–93.PubMedCrossRef
21.
Bakhtadze E, Cervin C, Lindholm E, Borg H, Nilsson P, Arnqvist HJ, et al. Common variants in the TCF7L2 gene help to differentiate autoimmune from non-autoimmune diabetes in young (15–34 years) but not in middle-aged (40–59 years) diabetic patients. Diabetologia. 2008;51:2224–32.PubMedCrossRef
22.
Zampetti S, Spoletini M, Petrone A, Capizzi M, Arpi ML, Tiberti C, et al. Association of TCF7L2 gene variants with low GAD autoantibody titre in LADA subjects (NIRAD Study 5). Diabet Medicine: J Br Diabet Association. 2010;27:701–4.CrossRef
23.
Andersen MK. New insights into the Genetics of Latent Autoimmune diabetes in adults. Curr Diab Rep. 2020;20:43.PubMedCrossRef
24.
Shi X, Huang G, Wang Y, Liu Z, Deng C, Li X, et al. Tetraspanin 7 autoantibodies predict progressive decline of beta cell function in individuals with LADA. Diabetologia. 2019;62:399–407.PubMedCrossRef
25.
Yang L, Zhou ZG, Tan SZ, Huang G, Jin P, Yan X, et al. Carboxypeptidase-H autoantibodies differentiate a more latent subset of autoimmune diabetes from phenotypic type 2 diabetes among Chinese adults. Ann N Y Acad Sci. 2008;1150:263–6.PubMedCrossRef
26.
Tiberti C, Giordano C, Locatelli M, Bosi E, Bottazzo GF, Buzzetti R, et al. Identification of tyrosine phosphatase 2(256–760) construct as a new, sensitive marker for the detection of islet autoimmunity in type 2 diabetic patients: the non-insulin requiring autoimmune diabetes (NIRAD) study 2. Diabetes. 2008;57:1276–83.PubMedCrossRef
27.
Tiberti C, Zampetti S, Capoccia D, Campagna G, Lucantoni F, Anastasi E, et al. Evidence of diabetes-specific autoimmunity in obese subjects with normal glucose tolerance. Diab/Metab Res Rev. 2018;34:e3055.CrossRef
28.
Hu J, Zhang R, Zou H, Xie L, Zhou Z, Xiao Y. Latent autoimmune diabetes in adults (LADA): from immunopathogenesis to Immunotherapy. Front Endocrinol. 2022;13:917169.CrossRef
29.
Crudele L, Gadaleta RM, Cariello M, Moschetta A. Gut microbiota in the pathogenesis and therapeutic approaches of diabetes. EBioMedicine. 2023;97:104821.PubMedPubMedCentralCrossRef
30.
Fang Y, Zhang C, Shi H, Wei W, Shang J, Zheng R, et al. Characteristics of the gut microbiota and metabolism in patients with latent autoimmune diabetes in adults: a case-control study. Diabetes Care. 2021;44:2738–46.PubMedPubMedCentralCrossRef
31.
Li D, Li Y, Yang S, Lu J, Jin X, Wu M. Diet-gut microbiota-epigenetics in metabolic diseases: from mechanisms to therapeutics. Volume 153. Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie; 2022. p. 113290.
32.
Aljutaily T, Consuegra-Fernández M, Aranda F, Lozano F, Huarte E. Gut microbiota metabolites for sweetening type I diabetes. Cell Mol Immunol. 2018;15:92–5.PubMedCrossRef
33.
Kim CH. Microbiota or short-chain fatty acids: which regulates diabetes? Cell Mol Immunol. 2018;15:88–91.PubMedCrossRef
34.
Mariño E, Richards JL, McLeod KH, Stanley D, Yap YA, Knight J, et al. Gut microbial metabolites limit the frequency of autoimmune T cells and protect against type 1 diabetes. Nat Immunol. 2017;18:552–62.PubMedCrossRef
35.
Wen L, Wong FS. Dietary short-chain fatty acids protect against type 1 diabetes. Nat Immunol. 2017;18:484–6.PubMedCrossRef
36.
37.
Yang L, Liu X, Liang H, Cheng Y, Huang G, Zhou Z. Pathophysiological characteristics in patients with latent autoimmune diabetes in adults using clamp tests: evidence of a continuous disease spectrum of diabetes. Acta Diabetol. 2019;56:1217–24.PubMedCrossRef
38.
Lin J, Zhou ZG, Wang JP, Zhang C, Huang G. From Type 1, through LADA, to type 2 diabetes: a continuous spectrum? Annals of the New York Academy of Sciences. 2008;1150:99–102.
39.
Mishra R, Chesi A, Cousminer DL, Hawa MI, Bradfield JP, Hodge KM, et al. Relative contribution of type 1 and type 2 diabetes loci to the genetic etiology of adult-onset, non-insulin-requiring autoimmune diabetes. BMC Med. 2017;15:88.PubMedPubMedCentralCrossRef
40.
Carry PM, Waugh K, Vanderlinden LA, Johnson RK, Buckner T, Rewers M, et al. Changes in the coexpression of Innate immunity genes during persistent islet autoimmunity are Associated with Progression of Islet autoimmunity: diabetes autoimmunity study in the Young (DAISY). Diabetes. 2022;71:2048–57.PubMedPubMedCentralCrossRef
41.
Hjort R, Ahlqvist E, Carlsson PO, Grill V, Groop L, Martinell M, et al. Overweight, obesity and the risk of LADA: results from a Swedish case-control study and the Norwegian HUNT study. Diabetologia. 2018;61:1333–43.PubMedPubMedCentralCrossRef
42.
Li X, Cao C, Tang X, Yan X, Zhou H, Liu J, et al. Prevalence of metabolic syndrome and its determinants in newly-diagnosed adult-onset diabetes in China: a Multi-Center, cross-sectional survey. Front Endocrinol. 2019;10:661.CrossRef
43.
Timakova AA, Saltykov BB. Features of the development of latent autoimmune diabetes in adults (LADA). Arkh Patol. 2019;81:78–82.PubMedCrossRef
44.
Brophy S, Yderstraede K, Mauricio D, Hunter S, Hawa M, Pozzilli P, et al. Time to insulin initiation cannot be used in defining latent autoimmune diabetes in adults. Diabetes Care. 2008;31:439–41.PubMedCrossRef
45.
Buzzetti R, Di Pietro S, Giaccari A, Petrone A, Locatelli M, Suraci C, et al. High titer of autoantibodies to GAD identifies a specific phenotype of adult-onset autoimmune diabetes. Diabetes Care. 2007;30:932–8.PubMedCrossRef
46.
Zhou Z, Xiang Y, Ji L, Jia W, Ning G, Huang G, et al. Frequency, immunogenetics, and clinical characteristics of latent autoimmune diabetes in China (LADA China study): a nationwide, multicenter, clinic-based cross-sectional study. Diabetes. 2013;62:543–50.PubMedPubMedCentralCrossRef
47.
Hawa MI, Kolb H, Schloot N, Beyan H, Paschou SA, Buzzetti R, et al. Adult-onset autoimmune diabetes in Europe is prevalent with a broad clinical phenotype: action LADA 7. Diabetes Care. 2013;36:908–13.PubMedPubMedCentralCrossRef
48.
Lohmann T, Kellner K, Verlohren HJ, Krug J, Steindorf J, Scherbaum WA, et al. Titre and combination of ICA and autoantibodies to glutamic acid decarboxylase discriminate two clinically distinct types of latent autoimmune diabetes in adults (LADA). Diabetologia. 2001;44:1005–10.PubMedCrossRef
49.
Lu J, Hou X, Zhang L, Hu C, Zhou J, Pang C, et al. Associations between clinical characteristics and chronic complications in latent autoimmune diabetes in adults and type 2 diabetes. Diab/Metab Res Rev. 2015;31:411–20.CrossRef
50.
Maddaloni E, Coleman RL, Agbaje O, Buzzetti R, Holman RR. Time-varying risk of microvascular complications in latent autoimmune diabetes of adulthood compared with type 2 diabetes in adults: a post-hoc analysis of the UK prospective diabetes study 30-year follow-up data (UKPDS 86). Lancet Diabetes Endocrinol. 2020;8:206–15.PubMedCrossRef
51.
Lu J, Ma X, Zhang L, Mo Y, Ying L, Lu W, et al. Glycemic variability assessed by continuous glucose monitoring and the risk of diabetic retinopathy in latent autoimmune diabetes of the adult and type 2 diabetes. J Diabetes Invest. 2019;10:753–9.CrossRef
52.
Maddaloni E, Coleman RL, Pozzilli P, Holman RR. Long-term risk of cardiovascular disease in individuals with latent autoimmune diabetes in adults (UKPDS 85). Diabetes Obes Metab. 2019;21:2115–22.PubMedCrossRef
53.
Wod M, Thomsen RW, Pedersen L, Yderstraede KB, Beck-Nielsen H, Højlund K. Lower mortality and cardiovascular event rates in patients with latent autoimmune diabetes in adults (LADA) as compared with type 2 diabetes and insulin deficient diabetes: a cohort study of 4368 patients. Diabetes Res Clin Pract. 2018;139:107–13.PubMedCrossRef
54.
Olsson L, Grill V, Midthjell K, Ahlbom A, Andersson T, Carlsson S. Mortality in adult-onset autoimmune diabetes is associated with poor glycemic control: results from the HUNT study. Diabetes Care. 2013;36:3971–8.PubMedPubMedCentralCrossRef
55.
Baum P, Hermann W, Verlohren HJ, Wagner A, Lohmann T, Grahmann F. Diabetic neuropathy in patients with latent autoimmune diabetes of the adults (LADA) compared with patients with type 1 and type 2 diabetes. J Neurol. 2003;250:682–7.PubMedCrossRef
56.
Alam U, Jeziorska M, Petropoulos IN, Pritchard N, Edwards K, Dehghani C, et al. Latent autoimmune diabetes of adulthood (LADA) is associated with small fibre neuropathy. Diabet Medicine: J Br Diabet Association. 2019;36:1118–24.CrossRef
57.
Issar T, Yan A, Kwai NCG, Poynten AM, Borire AA, Arnold R, et al. Altered peripheral nerve structure and function in latent autoimmune diabetes in adults. Diab/Metab Res Rev. 2020;36:e3260.CrossRef
58.
Xiang Y, Huang G, Zhu Y, Zuo X, Liu X, Feng Q, et al. Identification of autoimmune type 1 diabetes and multiple organ-specific autoantibodies in adult-onset non-insulin-requiring diabetes in China: a population-based multicentre nationwide survey. Diabetes Obes Metab. 2019;21:893–902.PubMedCrossRef
59.
Głowińska-Olszewska B, Michalak J, Łuczyński W, Del Pilar Larosa M, Chen S, Furmaniak J, et al. Organ-specific autoimmunity in relation to clinical characteristics in children with long-lasting type 1 diabetes. J Pediatr Endocrinol Metabolism: JPEM. 2016;29:647–56.CrossRef
60.
Milluzzo A, Falorni A, Brozzetti A, Pezzino G, Tomaselli L, Tumminia A, et al. Risk for Coexistent Autoimmune diseases in Familial and sporadic type 1 diabetes is related to age at diabetes onset. Endocr Practice: Official J Am Coll Endocrinol Am Association Clin Endocrinologists. 2021;27:110–7.CrossRef
61.
Gougourelas D, Tsentidis C, Koufadaki AM, Koutsovasilis A, Gougourela E, Karanasios S, et al. Associated autoimmunity in type 1 diabetes and latent autoimmune diabetes of adults: the role of glutamic-acid decarboxylase autoantibodies. Diabetes Res Clin Pract. 2021;175:108847.PubMedCrossRef
62.
Wang W, Mao J, Zhao J, Lu J, Yan L, Du J, et al. Decreased thyroid peroxidase antibody titer in response to Selenium Supplementation in Autoimmune Thyroiditis and the influence of a selenoprotein P gene polymorphism: a prospective, Multicenter Study in China. Thyroid: Official J Am Thyroid Association. 2018;28:1674–81.CrossRef
63.
Kakleas K, Kostaki M, Critselis E, Karayianni C, Giannaki M, Anyfantakis K, et al. Gastric autoimmunity in children and adolescents with type 1 diabetes: a prospective study. Hormone Res Paediatrics. 2012;77:121–6.CrossRef
64.
Zampetti S, Campagna G, Tiberti C, Songini M, Arpi ML, De Simone G, et al. High GADA titer increases the risk of insulin requirement in LADA patients: a 7-year follow-up (NIRAD study 7). Eur J Endocrinol. 2014;171:697–704.PubMedCrossRef
65.
Yin W, Luo S, Xiao Z, Zhang Z, Liu B, Zhou Z. Latent autoimmune diabetes in adults: a focus on β-cell protection and therapy. Front Endocrinol. 2022;13:959011.CrossRef
66.
Pieralice S, Pozzilli P. Latent autoimmune diabetes in adults: a review on clinical implications and management. Diabetes Metabolism J. 2018;42:451–64.CrossRef
67.
Yang Z, Zhou Z, Li X, Huang G, Lin J. Rosiglitazone preserves islet beta-cell function of adult-onset latent autoimmune diabetes in 3 years follow-up study. Diabetes Res Clin Pract. 2009;83:54–60.PubMedCrossRef
68.
Hals IK, Fiskvik Fleiner H, Reimers N, Astor MC, Filipsson K, Ma Z, et al. Investigating optimal β-cell-preserving treatment in latent autoimmune diabetes in adults: results from a 21-month randomized trial. Diabetes Obes Metab. 2019;21:2219–27.PubMedCrossRef
69.
Hals IK. Treatment of latent autoimmune diabetes in adults: what is best? Curr Diabetes Rev. 2019;15:188–93.PubMedCrossRef
70.
Yang X, Deng H, Zhang X, Yang D, Yan J, Yao B, et al. Insulin requirement profiles and related factors of insulin pump therapy in patients with type 2 diabetes. Sci China Life Sci. 2019;62:1506–13.PubMedCrossRef
71.
Pickup JC, Reznik Y, Sutton AJ. Glycemic Control during continuous Subcutaneous insulin infusion Versus multiple daily insulin injections in type 2 diabetes: Individual Patient Data Meta-Analysis and Meta-regression of Randomized controlled trials. Diabetes Care. 2017;40:715–22.PubMedCrossRef
72.
Campbell-Thompson M, Fu A, Kaddis JS, Wasserfall C, Schatz DA, Pugliese A, et al. Insulitis and β-Cell Mass in the natural history of type 1 diabetes. Diabetes. 2016;65:719–31.PubMedCrossRef
73.
Sudan A, Kalra A, Mirza AA, Kant R. Efficacy of DPP-4 inhibitors and SGLT2 inhibitors compared to sulphonylureas in adult patients with diabetes with low c-peptide levels with or without anti-GAD65 antibody positivity. Diabetes Metabolic Syndrome. 2021;15:102197.PubMedCrossRef
74.
Wang X, Yang L, Cheng Y, Zheng P, Hu J, Huang G, et al. Altered T-cell subsets and transcription factors in latent autoimmune diabetes in adults taking sitagliptin, a dipeptidyl peptidase-4 inhibitor: a 1-year open-label randomized controlled trial. J Diabetes Invest. 2019;10:375–82.CrossRef
75.
Pozzilli P, Leslie RD, Peters AL, Buzzetti R, Shankar SS, Milicevic Z et al. Dulaglutide treatment results in effective glycaemic control in latent autoimmune diabetes in adults (LADA): A post-hoc analysis of the AWARD-2, -4 and – 5 Trials. Diabetes, obesity & metabolism. 2018;20:1490-8.
76.
Casas R, Dietrich F, Barcenilla H, Tavira B, Wahlberg J, Achenbach P, et al. Glutamic acid decarboxylase injection into Lymph nodes: Beta cell function and Immune responses in recent onset type 1 diabetes patients. Front Immunol. 2020;11:564921.PubMedPubMedCentralCrossRef
77.
Ludvigsson J, Sumnik Z, Pelikanova T, Nattero Chavez L, Lundberg E, Rica I, et al. Intralymphatic glutamic acid decarboxylase with vitamin D supplementation in recent-onset type 1 diabetes: a Double-Blind, randomized, placebo-controlled phase IIb trial. Diabetes Care. 2021;44:1604–12.PubMedPubMedCentralCrossRef
78.
Hannelius U, Beam CA, Ludvigsson J. Efficacy of GAD-alum immunotherapy associated with HLA-DR3-DQ2 in recently diagnosed type 1 diabetes. Diabetologia. 2020;63:2177–81.PubMedPubMedCentralCrossRef
79.
Nowak C, Lind M, Sumnik Z, Pelikanova T, Nattero-Chavez L, Lundberg E, et al. Intralymphatic GAD-Alum (Diamyd®) improves Glycemic Control in Type 1 diabetes with HLA DR3-DQ2. J Clin Endocrinol Metab. 2022;107:2644–51.PubMedPubMedCentralCrossRef
80.
Björklund A, Hals IK, Grill V, Ludvigsson J. Latent autoimmune diabetes in adults: background, Safety and Feasibility of an Ongoing Pilot Study with Intra-lymphatic injections of GAD-Alum and oral vitamin D. Front Endocrinol. 2022;13:926021.CrossRef
81.
Hou Y, Song A, Jin Y, Xia Q, Song G, Xing X. A dose-response meta-analysis between serum concentration of 25-hydroxy vitamin D and risk of type 1 diabetes mellitus. Eur J Clin Nutr. 2021;75:1010–23.PubMedCrossRef
82.
Infante M, Ricordi C, Sanchez J, Clare-Salzler MJ, Padilla N, Fuenmayor V et al. Influence of vitamin D on Islet autoimmunity and Beta-cell function in type 1 diabetes. Nutrients. 2019;11.
83.
Pinheiro MM, Pinheiro FMM, Trabachin ML. Dipeptidyl peptidase-4 inhibitors (DPP-4i) combined with vitamin D3: an exploration to treat new-onset type 1 diabetes mellitus and latent autoimmune diabetes in adults in the future. Int Immunopharmacol. 2018;57:11–7.PubMedCrossRef
84.
Pinheiro MM, Pinheiro FMM, Diniz SN, Fabbri A, Infante M. Combination of vitamin D and dipeptidyl peptidase-4 inhibitors (VIDPP-4i) as an immunomodulation therapy for autoimmune diabetes. Int Immunopharmacol. 2021;95:107518.PubMedCrossRef
85.
Baeke F, Takiishi T, Korf H, Gysemans C, Mathieu C. Vitamin D: modulator of the immune system. Curr Opin Pharmacol. 2010;10:482–96.PubMedCrossRef
86.
Zhang R, Xiao Y, Yan J, Yang W, Wu X, Mei Z, et al. Effects of Berberine Plus Inulin on Diabetes Care in patients with latent autoimmune diabetes in adults: protocol for a Randomized Controlled Trial. Front Endocrinol. 2022;13:876657.CrossRef
87.
Zhou D, Li X, Xiao X, Wang G, Chen B, Song Y, et al. Celastrol targets the ChREBP-TXNIP axis to ameliorates type 2 diabetes mellitus. Phytomedicine: Int J Phytotherapy Phytopharmacology. 2023;110:154634.CrossRef
88.
Buse JB, Wexler DJ, Tsapas A, Rossing P, Mingrone G, Mathieu C, et al. 2019 Update to: management of hyperglycemia in type 2 diabetes, 2018. A Consensus Report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetes Care. 2020;43:487–93.PubMedCrossRef
89.
Gu Y, Jia X, Vartak T, Miao D, Dong F, Jerram ST, et al. Improving clinical utility of GAD65 autoantibodies by electrochemiluminescence assay and clinical phenotype when identifying autoimmune adult-onset diabetes. Diabetologia. 2021;64:2052–60.PubMedPubMedCentralCrossRef
90.
Sørgjerd EP, Åsvold BO, Grill V. Low C-peptide together with a high glutamic acid decarboxylase autoantibody level predicts progression to insulin dependence in latent autoimmune diabetes in adults: the HUNT study. Diabetes Obes Metab. 2021;23:2539–50.PubMedCrossRef
91.
Sugiyama K, Saisho Y. Predicting non-insulin-dependent state in patients with slowly progressive insulin-dependent (type 1) diabetes mellitus or latent autoimmune diabetes in adults. Diabetologia. 2022;65:250–1.PubMedCrossRef
Metadata
Title
Prognosis and outcome of latent autoimmune diabetes in adults: T1DM or T2DM?
Authors
Zhipeng Zhou
Mingyue Xu
Pingjie Xiong
Jing Yuan
Deqing Zheng
Shenghua Piao
Publication date
01-12-2024

Other articles of this Issue 1/2024

Current and past depression as risk factors for incident type 2 diabetes mellitus and pre-diabetes in men and women: evidence from a longitudinal community cohort

Predictive value of insulin resistance surrogates for the development of diabetes in individuals with baseline normoglycemia: findings from two independent cohort studies in China and Japan

Obesity and 1-year all-cause survival of adult intensive care patients with heart failure: data from the MIMIC-IV.

Effects of glycaemic control on memory performance, hippocampal volumes and depressive symptomology

Metformin plus lifestyle interventions versus lifestyle interventions alone for the delay or prevention of type 2 diabetes in individuals with prediabetes: a meta-analysis of randomized controlled trials

Dapagliflozin improves podocytes injury in diabetic nephropathy via regulating cholesterol balance through KLF5 targeting the ABCA1 signalling pathway

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine
Read more
Image Credits